NL13, a novel curcumin analogue and polo like kinase 4 inhibitor, induces cell cycle arrest and apoptosis in prostate cancer models.

Xinyi QiaoKe ZhengLei YeJin YangRong CuiYuanyuan ShanXiaoheng LiHuitao LiQiqi ZhuZhiguang ZhaoRen-Shan GeYiyan Wang

Published in: British journal of pharmacology (2024)

NL13, a novel PLK4-targeted curcumin analogue, exerts promising anticancer properties against prostate cancer by disrupting the PLK4-AKT-CCNB1/CDK1 and apoptosis pathways. NL13 represents a promising new agent for prostate cancer therapy.

Keyphrases

cell cycle arrest
prostate cancer
cancer therapy
cell death
pi k akt
radical prostatectomy
signaling pathway
drug delivery
cell proliferation
cell cycle
endoplasmic reticulum stress